Nkarta to Participate in an Upcoming Investor Conference
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
加利福尼亞南三藩市，2024年11月26日(GLOBE NEWSWIRE) - 生物製藥公司nkarta，Inc. (納斯達克：NKTX) 宣佈，一家生物技術公司開發工程化天然殺傷NK細胞療法，今天宣佈其參加以下投資者會議：
7th Annual Evercore HealthCONx Conference
December 4, 2024
2:10 p.m. ET – fireside chat
第七屆evercore HealthCONx大會
2024年12月4日
美國東部時間下午2點10分 - 爐邊聊天
A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, , and a replay will be archived on the website for approximately 90 days.
該活動的同時網絡直播將在Nkarta網站的投資者版塊上提供，並將在網站上存檔回放約90天。
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at .
關於Nkarta
nkarta是一家處於臨床階段的生物技術公司，正在推動異基因、現貨天然殺傷細胞（NK細胞）療法的開發。nkarta通過將其細胞擴增和冷凍保存平台與專有的細胞工程技術以及基於CRISPR的基因組工程能力相結合，正在打造未來細胞療法的管線，旨在爲門診治療環境提供廣泛使用的經過深度治療活性改造的細胞療法。欲了解更多信息，請訪問該公司的網站。
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
Nkarta媒體/投資者聯繫人：
Greg Mann
Nkarta公司
gmann@nkartatx.com
譯文內容由第三人軟體翻譯。
